[go: up one dir, main page]

PE20190336A1 - Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
PE20190336A1
PE20190336A1 PE2018001293A PE2018001293A PE20190336A1 PE 20190336 A1 PE20190336 A1 PE 20190336A1 PE 2018001293 A PE2018001293 A PE 2018001293A PE 2018001293 A PE2018001293 A PE 2018001293A PE 20190336 A1 PE20190336 A1 PE 20190336A1
Authority
PE
Peru
Prior art keywords
contain
preparation
pharmaceutical compositions
branched
straight
Prior art date
Application number
PE2018001293A
Other languages
English (en)
Inventor
Attila Paczal
Zoltan Szlavik
Andras Kotschy
Maia Chanrion
Ana Leticia Maragno
Olivier Geneste
Didier Demarles
Balazs Balint
Szabolcs Sipos
Original Assignee
Servier Lab
Vernalis Randd Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Vernalis Randd Ltd filed Critical Servier Lab
Publication of PE20190336A1 publication Critical patent/PE20190336A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

Referido a un compuesto de formula (I), en la que Y es -NH o un atomo de oxigeno; R1 es alquilo(C1-C6) lineal o ramificado, un grupo alcoxi(C1-C6) lineal o ramificado, entre otros; R2, R3 y R4 independientemente uno de otro, representan H, halogeno, alquilo(C1-C6) lineal o ramificado; R5 es un atomo de hidrogeno; R6 representa el grupo (a), sus enantiomeros, diastereoisomeros y atropisomeros, y sales de adicion de estos con un acido o base farmaceuticamente aceptable. Un compuesto seleccionado es: hidrogeno fosfato de {4-[2-(4-{(5Sa)-4-[(1R)-1-carboxi-2-(2-{[2-(2-metoxifenil)pirimidin-4-il]metoxi}fenil)etoxi]-6-(4-fluorofenil)tieno[2,3-d]pirimidin-5-il}-2-cloro-3-metilfenoxi)etil]-1-metilpiperacin-1-io-1-il}metilo. Tambien se refiere a un proceso para su preparacion, composiciones farmaceuticas que los contienen y su uso en el tratamiento del cancer.
PE2018001293A 2016-01-19 2016-12-19 Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen PE20190336A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1650411A FR3046792B1 (fr) 2016-01-19 2016-01-19 Nouveaux derives d'ammonium, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
PE20190336A1 true PE20190336A1 (es) 2019-03-07

Family

ID=55752504

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001293A PE20190336A1 (es) 2016-01-19 2016-12-19 Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen

Country Status (43)

Country Link
US (1) US10457689B2 (es)
EP (1) EP3405471B1 (es)
JP (1) JP6871275B2 (es)
KR (1) KR102805983B1 (es)
CN (1) CN108602841B (es)
AU (1) AU2016387870B2 (es)
BR (1) BR112018014536B1 (es)
CA (1) CA3011761C (es)
CL (1) CL2018001908A1 (es)
CO (1) CO2018007443A2 (es)
CR (1) CR20180363A (es)
CU (1) CU20180073A7 (es)
CY (1) CY1122560T1 (es)
DK (1) DK3405471T3 (es)
EA (1) EA036932B1 (es)
EC (1) ECSP18053634A (es)
ES (1) ES2760545T3 (es)
FR (1) FR3046792B1 (es)
GE (1) GEP20207126B (es)
HR (1) HRP20192073T1 (es)
HU (1) HUE048449T2 (es)
IL (1) IL260550B (es)
LT (1) LT3405471T (es)
MA (1) MA43639B1 (es)
MD (1) MD3405471T2 (es)
ME (1) ME03555B (es)
MX (1) MX376028B (es)
MY (1) MY196352A (es)
NI (1) NI201800076A (es)
PE (1) PE20190336A1 (es)
PH (1) PH12018501506A1 (es)
PL (1) PL3405471T3 (es)
PT (1) PT3405471T (es)
RS (1) RS59622B1 (es)
RU (1) RU2743098C2 (es)
SA (1) SA518392049B1 (es)
SG (1) SG11201805913QA (es)
SI (1) SI3405471T1 (es)
SV (1) SV2018005722A (es)
TN (1) TN2018000239A1 (es)
UA (1) UA123508C2 (es)
WO (1) WO2017125224A1 (es)
ZA (1) ZA201804770B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3037956B1 (fr) * 2015-06-23 2017-08-04 Servier Lab Nouveaux derives d'acide amine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3037958B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxy-acide, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
UY37560A (es) 2017-01-06 2018-07-31 Servier Lab Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
RU2763544C2 (ru) * 2017-01-06 2021-12-30 Ле Лаборатуар Сервье Комбинация mcl-1 ингибитора и таксанового соединения, их применения и фармацевтические композиции
EA202090082A1 (ru) 2017-06-22 2020-05-22 Ле Лаборатуар Сервье Комбинация ингибитора mcl-1 и стандартного лекарственного препарата для лечения гематологических злокачественных новообразований, ее применение и содержащие ее фармацевтические композиции
WO2019035911A1 (en) 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC INHIBITORS OF MCL-1 AND METHODS OF USE
TW201920193A (zh) * 2017-08-15 2019-06-01 美商艾伯維有限公司 大環mel-1抑制劑以及使用方法
WO2019035914A1 (en) * 2017-08-15 2019-02-21 Abbvie Inc. MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE
CN108424417B (zh) * 2017-12-21 2019-09-20 河南真实生物科技有限公司 噻吩并嘧啶衍生物、其制备方法及在制备抗肿瘤药物中的应用
AR116635A1 (es) 2018-10-15 2021-05-26 Servier Lab Proceso para la síntesis de derivados de piperazinil-etoxi-bromofenilo y su aplicación en la producción de compuestos que los contienen
TWI849001B (zh) 2018-11-14 2024-07-21 法商施維雅藥廠 Mcl-1抑制劑及米哚妥林(midostaurin)之組合,其用途及醫藥組合物
AR117255A1 (es) * 2018-12-06 2021-07-21 Servier Lab Formas cristalinas de un inhibidor de mcl-1, un proceso para su preparación y composiciones farmacéuticas que las contienen
WO2020236825A2 (en) * 2019-05-20 2020-11-26 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
AR119156A1 (es) 2019-06-17 2021-11-24 Servier Lab Combinación de un inhibidor de mcl-1 y un tratamiento estándar de atención médica para cáncer de mama, usos y composiciones farmacéuticas de la misma
AU2020358967A1 (en) * 2019-10-03 2022-05-19 1200 Pharma Llc MCL1 inhibitors and uses thereof
CA3202759A1 (en) 2020-11-24 2022-06-02 Novartis Ag Mcl-1 inhibitor antibody-drug conjugates and methods of use
WO2022216946A1 (en) * 2021-04-07 2022-10-13 California Institute Of Technology Mcl1 inhibitors and uses thereof
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
WO2022261310A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-body drug conjugates
IL317101A (en) 2022-05-20 2025-01-01 Novartis Ag Antibody-drug conjugates of anticancer compounds and methods of using them
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
CA2280181A1 (en) * 1997-02-09 1998-08-13 Pharmos Corporation Enhanced anti-angiogenic activity of permanently charged derivatives of steroid hormones
AU2005260077A1 (en) * 2004-06-29 2006-01-12 Amgen Inc. Furanopyrimidines
CA2702838A1 (en) * 2007-10-16 2009-04-23 Wyeth Llc Thienopyrimidine and pyrazolopyrimidine compounds and their use as mtor kinase and pi3 kinase inhibitors
ES2616255T3 (es) * 2008-04-30 2017-06-12 National Health Research Institutes Compuestos de pirimidina bicíclicos condensados como inhibidores de las aurora cinasas
CN102264745B (zh) * 2008-11-10 2015-07-22 财团法人卫生研究院 作为酪胺酸激酶抑制剂的稠合双环及多环嘧啶化合物
CN102464667B (zh) * 2010-11-03 2014-06-04 中国科学院上海药物研究所 一类五元杂环并嘧啶类化合物及其制备方法和用途
RU2015118985A (ru) * 2012-11-14 2017-01-10 Ф. Хоффманн-Ля Рош Аг Производные имидазопиридина
HRP20181141T1 (hr) * 2013-05-02 2018-09-21 F. Hoffmann - La Roche Ag Derivati purina kao agonisti cb2 receptora
FR3015483B1 (fr) * 2013-12-23 2016-01-01 Servier Lab Nouveaux derives de thienopyrimidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EA201891622A1 (ru) 2019-01-31
CY1122560T1 (el) 2021-01-27
MX376028B (es) 2025-03-07
LT3405471T (lt) 2019-12-10
RU2018129308A3 (es) 2020-02-20
GEP20207126B (en) 2020-06-25
UA123508C2 (uk) 2021-04-14
ECSP18053634A (es) 2018-07-31
US20190031677A1 (en) 2019-01-31
SG11201805913QA (en) 2018-08-30
RU2018129308A (ru) 2020-02-20
TN2018000239A1 (en) 2020-01-16
HUE048449T2 (hu) 2020-07-28
CA3011761A1 (en) 2017-07-27
ES2760545T3 (es) 2020-05-14
ZA201804770B (en) 2021-08-25
MX2018008808A (es) 2018-09-21
FR3046792A1 (es) 2017-07-21
SV2018005722A (es) 2018-10-10
IL260550B (en) 2021-06-30
EA036932B1 (ru) 2021-01-18
CU20180073A7 (es) 2018-11-06
JP2019511559A (ja) 2019-04-25
CA3011761C (en) 2020-10-27
SA518392049B1 (ar) 2022-08-04
BR112018014536A2 (pt) 2018-12-11
NI201800076A (es) 2018-09-20
MY196352A (en) 2023-03-24
CN108602841B (zh) 2021-03-23
PL3405471T3 (pl) 2020-04-30
KR20180098677A (ko) 2018-09-04
PT3405471T (pt) 2019-12-05
MD3405471T2 (ro) 2020-02-29
SI3405471T1 (sl) 2020-02-28
MA43639B1 (fr) 2020-02-28
ME03555B (me) 2020-07-20
EP3405471B1 (en) 2019-10-30
CL2018001908A1 (es) 2019-01-04
HRP20192073T1 (hr) 2020-02-21
DK3405471T3 (da) 2020-01-27
AU2016387870A1 (en) 2018-07-26
CN108602841A (zh) 2018-09-28
CO2018007443A2 (es) 2018-07-19
FR3046792B1 (fr) 2018-02-02
KR102805983B1 (ko) 2025-05-09
RU2743098C2 (ru) 2021-02-15
RS59622B1 (sr) 2020-01-31
BR112018014536B1 (pt) 2022-10-11
EP3405471A1 (en) 2018-11-28
US10457689B2 (en) 2019-10-29
NZ744408A (en) 2025-02-28
AU2016387870B2 (en) 2021-04-01
PH12018501506A1 (en) 2019-04-08
CR20180363A (es) 2018-08-22
WO2017125224A1 (en) 2017-07-27
JP6871275B2 (ja) 2021-05-12

Similar Documents

Publication Publication Date Title
PE20190336A1 (es) Nuevos derivados de amonio, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20151601A1 (es) Compuestos novedosos de pirimidina y piridina y su uso
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR065556A1 (es) Derivados de 3-(( 1,2,4) triazolo (4,3-a) piridin -7-il) benzamida
PE20220502A1 (es) Compuestos utiles como inhibidores de cinasa
PE20190437A1 (es) Procesos para la preparacion de (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidin-1-carboxamida y sales del mismo
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
CL2017002609A1 (es) Compuestos derivados de pirazolopiridina hidrogenadas, inhibidores p2x7, composición farmacéutica que los comprende; proceso de preparación de estos; y su uso en el tratamiento de enfermedades oseas, sns, cardiovasculares, entre otras (divisional de cl 2655-2015)
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
PE20151951A1 (es) Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b
AR067886A1 (es) Derivados de acido azabifenilaminobenzoico
PH12016501440A1 (en) Novel heterocyclic compounds
AR078786A1 (es) Derivados de la cromenona
NZ622769A (en) Benzothiazol-6-yl acetic acid derivatives and their use for treating an hiv infection
EA201170099A1 (ru) Замещенные пиримидин-4-оновые производные
NZ705589A (en) Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
AR092876A1 (es) Inhibidores no nucleosidos de la transcriptasa inversa
PE20081845A1 (es) Nuevos derivados de aminopirimidina como inhibidores de plk1
PE20171341A1 (es) Compuestos de pirazina para el tratamiento de enfermedades infecciosas
PE20141351A1 (es) Triazolopiridinas
AR085489A1 (es) Derivados de triazolopiridinas, composiciones farmaceuticas que los contienen, proceso para prepararlos, intermediarios de dicho proceso y uso de los mismos para el tratamiento de enfermedades autoinmunes e inflamatorias
PE20090493A1 (es) DERIVADOS DE LA 6-CICLOAMINO-3-(PIRIDAZIN-4-IL)IMIDAZO[1,2-b]-PIRIDAZINA, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
EA201170096A1 (ru) Замещенные производные пиримидона